Applications of Allylestrenol in Industrial Manufacturing

Allylestrenol serves as a key synthetic progestogen with established roles in reproductive health pharmaceuticals and related synthesis. Our facilities deliver high-purity material for specialized sectors requiring controlled process integration, precise formulation, and compliance with stringent international standards. The following sections outline the primary industrial application pathways, with detailed technical parameters for each segment.

1. Reproductive Health Pharmaceuticals

Pharmaceutical firms incorporate allylestrenol as an active pharmaceutical ingredient (API) in oral and injectable dosage forms designed for hormone replacement therapy and management of threatened miscarriage. Downstream formulators depend on tight control of assay value, impurity profile, and crystalline state during tableting or capsule filling. Regulatory certification and full traceability are required to enter regulated international markets, especially for finished endocrine drug products.

Industry compliance standards

• USP (United States Pharmacopeia) Monograph for Allylestrenol
• Ph. Eur. (European Pharmacopoeia) quality requirements
• ICH Q7 GMP for API manufacturing
• European Union Directive 2001/83/EC for Medicinal Products

Typical usage ratio

• 2–10 mg per oral tablet or capsule, according to finished dosage specification
• Bulk formulation: 0.05–2% w/w in blend, adjusted to achieve pharmacopoeial potency

Downstream process integration

• Direct blending into granulation matrix following micronization
• API addition during wet or dry granulation, followed by compaction and coating
• Filtration and sterilization for injectables during aseptic fill-finish

Final product types

• Prescription oral tablets for threatened miscarriage
• Soft gelatin capsules for hormone support
• Injectable suspensions for women’s health therapies

2. Contract Development and Manufacturing (CDMO) for Generic Drug Production

Allylestrenol features in production lines at global or regional CDMO facilities focused on off-patent hormone therapies. These sites execute chemistry, manufacturing, and control (CMC) programs for licensed pharmaceutical manufacturers, requiring consistent batch reproducibility, validated synthesis routes, and comprehensive regulatory documentation from upstream material suppliers. Traceable supply streams and analytical batch release protocols ensure regulatory submission acceptance in major markets.

Industry compliance standards

• WHO GMP for active pharmaceutical ingredients
• FDA cGMP (21 CFR Parts 210/211) for US market entry
• ISO 9001:2015 for manufacturing quality management
• ANVISA requirements for Brazil

Typical usage ratio

• Pharmaceutical blend: 0.1–1% of batch weight, tailored to declared strength
• Precise scaling based on validated batch size between 25–2,000 L reactors

Downstream process integration

• Weighing and charging at the blending/feedstock stage
• In-process control for uniform dispersion during powder or granule mixing
• Stability sample retention for ongoing quality verification

Final product types

• Generic oral solid dosage forms for global pharmaceutical companies
• Multi-country registered API formulations for regional distributors
• Bulk packed API shipments for direct tableting or encapsulation

3. Bulk Steroid Intermediate Synthesis for Custom Steroid APIs

Fine chemical and pharmaceutical synthesis plants leverage allylestrenol as a precursor/reference molecule in multi-step synthesis routes for other custom steroidal APIs. The compound enters as a critical intermediate, subjected to functional group transformations, selective hydrogenation, or side-chain modification, underpinning new molecule development or further registered APIs. Characterization and batch uniformity are controlled via advanced analytical methods in compliance with global intermediate handling standards.

Industry compliance standards

• OECD GLP for analytical validation
• ICH Q11 for API starting materials/intermediates
• REACH registration for EU chemical intermediates
• Proper hazardous chemical handling under GHS

Typical usage ratio

• Utilized as process input in molar ratios defined by target synthetic transformation (e.g., 1.0–2.5 mol/step)
• Adjustment based on downstream conversion efficiency and byproduct profile

Downstream process integration

• Charged to reaction vessels at derivatization or hydrogenation stage
• In-line monitoring with NMR or HPLC to confirm intermediate conversion
• Purified by recrystallization, preparative chromatography, or filtration steps

Final product types

• Custom synthetic progestins for specialist drug development
• Steroidal intermediates for contraceptives and hormone regulation therapies
• Reference standards and internal markers for pharmaceutical R&D

4. Hormonal Veterinary Drug Formulation

Veterinary pharmaceutical companies use allylestrenol in tailored formulations for reproductive management in livestock and companion animals, including estrus synchronization products. Firms require material with defined particle size, impurity limits, and process documentation supporting VICH and national veterinary standards, ensuring animal safety and predictable pharmacokinetics. Manufacturing environments implement robust cross-contamination controls and pharmacovigilance readiness.

Industry compliance standards

• VICH GL9 (Good Manufacturing Practice for APIs in Veterinary Medicinal Products)
• Pharmacopoeia standards set by national veterinary authorities (e.g., BP Vet, USP–NF)
• National Pesticide and Veterinary Medicine Authority (APVMA) requirements
• ISO 22442 for animal tissue derivatives in pharmaceuticals

Typical usage ratio

• 0.5–5 mg per dose in target species, batch-specific adjustment by bodyweight
• Powder premix: 0.01–0.2% w/w, depending on formulation route (oral, injectable)

Downstream process integration

• Premix blending with feed grains for oral dosing products
• Sterile filtration before injection vial filling
• Integration into depot or sustained-release preparation using polymer carriers

Final product types

• Veterinary tablets and suspensions for reproductive management
• Injectable hormonal therapies for cattle, swine, and equine species
• Compounded paste/gel for estrus cycle regulation